Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
The purpose of this study is to see whether treatment with a drug called Pazopanib after surgery for kidney cancer and metastases will increase the time without cancer returning.
Metastatic Renal Cell Carcinoma
*Must be 18 years or older
*Patient must have pathology showing confirmed renal cell carcinoma with clear cell. Metastatic disease also needs to be confirmed through pathology
*Must have undergone surgery to remove kidney cancer at any time in the past.
*Must have undergone surgery to remove all known locations of metastases successfully 2 to 12 weeks before beginning study.
*No prior treatment for renal cell carcinoma.
*No evidence of disease on a CT or MRI within 4 weeks before beginning study.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 10 years.
Eastern Cooperative Oncology Group (ECOG)